Identification of SRSF2 as a potential immunodiagnostic biomarker for osteosarcoma: A study based on focused protein microarray

doi:10.5306/wjco.v17.i5.119275

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 17, Issue 5

This Article

(0) (0) (0) (124)

Peer-Review Report of This Article

CrossCheck and Google Search of This Article

Academic Rules and Norms of This Article

Supplementary Materials of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Times Cited of This Article

Times Cited (0)

Journal Information of This Article

Publication Name

World Journal of Clinical Oncology

ISSN

2218-4333

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Basic Study

Copyright: ©Author(s) 2026. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution-NonCommercial (CC BY-NC 4.0) license. No commercial re-use. See permissions. Published by Baishideng Publishing Group Inc.

World J Clin Oncol. May 24, 2026; 17(5): 119275
Published online May 24, 2026. doi: 10.5306/wjco.v17.i5.119275

Table 1 Characteristics of study subjects, mean ± SD/n (%)

Variables	Discovery cohort (n = 77)		Validation cohort (n = 137)
Variables	OS (n = 28)	NHS (n = 49)	OS (n = 49)	OC (n = 39)	NC (n = 49)
Age (year)	32.18 ± 19.31	40.09 ± 12.79	24.63 ± 14.84	18.77 ± 14.38	24.82 ± 11.47
Gender
Male	17 (60.71)	22 (44.90)	32 (65.31)	23 (58.97)	32 (65.31)
Female	11 (39.29)	27 (55.10)	17 (34.69)	16 (41.03)	17 (34.69)
Anatomic site
Left femur	7 (25.00)		14 (28.57)
Right femur	5 (17.86)		12 (24.49)
Left tibia	3 (10.71)		4 (8.16)
Right tibia	5 (17.86)		11 (22.45)
Right humerus	2 (7.14)		3 (6.12)
Others	6 (21.43)		5 (10.20)
Histologic type
Osteoblastic	5 (17.86)		8 (16.33)
Fibroblastic	3 (10.71)		4 (8.16)
Chondroblastic	4 (14.29)		8 (16.33)
Small cell OS	3 (10.71)		6 (12.24)
Others	4 (14.29)		7 (14.29)
Unknown	9 (32.17)		16 (32.65)
TNM
IA	12 (42.86)		25 (51.02)
IB	3 (10.71)		13 (26.53)
IIA	1 (3.57)		3 (6.12)
IIB	1 (3.57)		3 (6.12)
IV	11 (39.29)		1 (2.04)
Unknown	0 (0.00)		4 (8.16)
Tumor size
< 5 cm	8 (28.57)		10 (20.41)
≥ 5 cm	16 (57.14)		35 (71.43)
Unknown	4 (14.29)		4 (8.16)
Distant metastasis
No	17 (60.71)		48 (97.96)
Yes	11 (39.29)		1 (2.04)

OS: Osteosarcoma; TNM: Tumor-node-metastasis; NHS: Normal human sera; OC: Osteochondroma; NC: Normal control.

Full Size Table

Table 2 Optical density of autoantibodies of osteosarcoma, osteochondroma, and normal controls, median (25^th percentile-75^th percentile)

	OS	OC	NC	H	P value
GNA11	0.424 (0.295-0.705)	0.544 (0.324-0.962)	0.426 (0.357-0.506)	3.025	0.220
SRSF2	0.673 (0.524-0.845)	0.683 (0.315-1.051)	0.498 (0.311-0.793)	6.354	0.042
PIK3CA	0.727 (0.516-0.971)	0.708 (0.380-1.051)	0.827 (0.561-1.072)	3.846	0.146

GNA11: G-protein subunit alpha 11; SRSF2: Serine/arginine-rich splicing factor 2; PIK3CA: Phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha; OS: Osteosarcoma; OC: Osteochondroma; NC: Normal control.

Full Size Table

Citation: Ma Y, Wan L, Zhang YY, Luo YG, Yang N, Pu FF, Khan MIU, Liu M, Liu JS, Li JT. Identification of SRSF2 as a potential immunodiagnostic biomarker for osteosarcoma: A study based on focused protein microarray. World J Clin Oncol 2026; 17(5): 119275
URL: https://www.wjgnet.com/2218-4333/full/v17/i5/119275.htm
DOI: https://dx.doi.org/10.5306/wjco.v17.i5.119275

Ma Y, Wan L, Zhang YY, Luo YG, Yang N, Pu FF, Khan MIU, Liu M, Liu JS, Li JT. Identification of SRSF2 as a potential immunodiagnostic biomarker for osteosarcoma: A study based on focused protein microarray. World J Clin Oncol 2026; 17(5): 119275 [DOI: 10.5306/wjco.v17.i5.119275]

All content on this site: Copyright © 1993-2026 Baishideng Publishing Group Inc, its licensors, and contributors. All rights are reserved, including those for text and data mining, AI training, and similar technologies. For all open access content, the relevant licensing terms apply.